Leadership

Management

Jesper Wiklund

Chief Executive Officer

Jesper Wiklund joins Klaria from New York based Oberland Capital, a health care focused private investment firm with over $1.2 billion in capital commitments where he served as Managing Director, Europe. Prior to that, he was CEO of InDex Pharmaceuticals Holding AB, a drug development company listed on NASDAQ First North and based in Stockholm, Sweden. Over the course of his 20+ year career in the life science industry, Jesper Wiklund has completed strategic transactions with an aggregate value exceeding $1 billion and he has raised four rounds of Venture Capital from top-tier European Investors. He was born in 1969, holds an MBA from Harvard Business School and a Bachelor of Science in Biology from St. Mary’s College of California. Jesper Wiklund owns 1 203 654 shares in Klaria Pharma.

Scott Boyer

Chief Scientific Officer

Scott Boyer is a co-founder of Klaria. As Chief Scientific Officer, Scott Boyer oversees research, clinical development and regulatory affairs. Prior to joining Klaria, he was Chief Scientist at AstraZeneca with global responsibility for molecular and investigational toxicology across Astra Zeneca and he was a member of the AZ senior management team. Prior to that, he was Senior Research Scientist at Pfizer. Scott Boyer has a Ph.D from the University of Colorado, Boulder in Molecular Toxicology. He completed a NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute. Scott Boyer owns 725 010 shares in Klaria Pharma.

Marc Willuhn

Head of CMC

Marc Willuhn works as our Head of CMC (Chemistry, Manufacturing and Control). Previously, he was VP R&D at Fresenius Kabi and Head of the Innovation & Development Centre in Uppsala, Sweden. Prior to that, he was Director of Process Development at Baxter Healthcare. Earlier in his career, Marc Willuhn worked in chemical development at Schering AG and Sigma-Aldrich. He obtained his PhD in organic chemistry at the Max Planck Institute for Coal Research in Germany and carried out post-doctoral research at the Faculté de Pharmacie in Paris, France. Marc Willuhn does not own any shares in Klaria Pharma.

Board of Directors

Fredrik Hübinette

Chairman of the board since 2020. Fredrik Hübinette, born 1969, is the inventor and founder of Klaria Pharma Holding, Nicoccino Holding AB and UppsalaGruppen AB. He studied at Uppsala University and has held leading positions within different biotech companies for the last 20 years. Fredrik Hübinette owns 4 278 806 shares in Klaria Pharma.

Anders Ardstål

Member of the board since 2018. Anders Ardstål, born 1981, is an engineer and holds an MBA from Linköping University. He is Business Development Manager at Vitrolife Sweden AB and also serves on the boards of Intellego Technologies, Pmeverine AB, Euryphaessa AB and Proistami AB. He is independent of both the Company and major shareholders. Anders Ardstål owns 40 000 shares in Klaria Pharma.

Scott Boyer

Member of the board since 2015. Scott Boyer is a co-founder of Klaria. As Chief Scientific Officer, Scott Boyer oversees research, clinical development and regulatory affairs. Prior to joining Klaria, he was Chief Scientist at AstraZeneca with global responsibility for molecular and investigational toxicology across Astra Zeneca and he was a member of the AZ senior management team. Prior to that, he was Senior Research Scientist at Pfizer. Scott Boyer has a Ph.D from the University of Colorado, Boulder in Molecular Toxicology. He completed a NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute. Scott Boyer owns 725 010 shares in Klaria Pharma.